| Year |
Citation |
Score |
| 2023 |
Ramos A, Koch CE, Liu-Lupo Y, Hellinger RD, Kyung T, Abbott KL, Fröse J, Goulet D, Gordon KS, Eidell KP, Leclerc P, Whittaker CA, Larson RC, Muscato AJ, Yates KB, ... ... Hemann MT, et al. Leukemia-intrinsic determinants of CAR-T response revealed by iterative in vivo genome-wide CRISPR screening. Nature Communications. 14: 8048. PMID 38052854 DOI: 10.1038/s41467-023-43790-2 |
0.782 |
|
| 2023 |
Liu-Lupo Y, Ham JD, Jeewajee SKA, Nguyen L, Delorey T, Ramos A, Weinstock DM, Regev A, Hemann MT. Integrated multi-omics analyses reveal homology-directed repair pathway as a unique dependency in near-haploid leukemia. Blood Cancer Journal. 13: 92. PMID 37286545 DOI: 10.1038/s41408-023-00863-1 |
0.779 |
|
| 2023 |
Gordon KS, Kyung T, Perez CR, Holec PV, Ramos A, Zhang AQ, Agarwal Y, Liu Y, Koch CE, Starchenko A, Joughin BA, Lauffenburger DA, Irvine DJ, Hemann MT, Birnbaum ME. Author Correction: Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nature Biomedical Engineering. PMID 36737667 DOI: 10.1038/s41551-023-01006-4 |
0.712 |
|
| 2022 |
Gordon KS, Kyung T, Perez CR, Holec PV, Ramos A, Zhang AQ, Agarwal Y, Liu Y, Koch CE, Starchenko A, Joughin BA, Lauffenburger DA, Irvine DJ, Hemann MT, Birnbaum ME. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nature Biomedical Engineering. PMID 35710755 DOI: 10.1038/s41551-022-00896-0 |
0.748 |
|
| 2022 |
Dalin S, Grauman-Boss B, Lauffenburger DA, Hemann MT. Collateral responses to classical cytotoxic chemotherapies are heterogeneous and sensitivities are sparse. Scientific Reports. 12: 5453. PMID 35361803 DOI: 10.1038/s41598-022-09319-1 |
0.787 |
|
| 2021 |
Mueller HS, Fowler CE, Dalin S, Moiso E, Udomlumleart T, Garg S, Hemann MT, Lees JA. Acquired resistance to PRMT5 inhibition induces concomitant collateral sensitivity to paclitaxel. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34408017 DOI: 10.1073/pnas.2024055118 |
0.795 |
|
| 2021 |
Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Clare Beytagh M, Xuan L, Feldser DM, Hemann MT, Zamudio J, Dimitrova N, Letai A, Jacks T. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34074758 DOI: 10.1073/pnas.2019740118 |
0.791 |
|
| 2021 |
Roux B, Vaganay C, Vargas JD, Alexe G, Benaksas C, Pardieu B, Fenouille N, Ellegast JM, Malolepsza E, Ling F, Sodaro G, Ross L, Pikman Y, Conway AS, Tang Y, ... ... Hemann MT, et al. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Science Translational Medicine. 13. PMID 33790022 DOI: 10.1126/scitranslmed.abg1168 |
0.324 |
|
| 2020 |
Jiang T, Sánchez-Rivera FJ, Soto-Feliciano YM, Yang Q, Song CQ, Bhuatkar A, Haynes CM, Hemann MT, Xue W. Targeting de novo purine synthesis pathway via ADSL depletion impairs liver cancer growth by perturbing mitochondrial function. Hepatology (Baltimore, Md.). PMID 33336367 DOI: 10.1002/hep.31685 |
0.735 |
|
| 2020 |
Chatterjee N, Whitman MA, Harris CA, Min SM, Jonas O, Lien EC, Luengo A, Vander Heiden MG, Hong J, Zhou P, Hemann MT, Walker GC. REV1 inhibitor JH-RE-06 enhances tumor cell response to chemotherapy by triggering senescence hallmarks. Proceedings of the National Academy of Sciences of the United States of America. PMID 33168727 DOI: 10.1073/pnas.2016064117 |
0.36 |
|
| 2020 |
Vassel FM, Bian K, Walker GC, Hemann MT. Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 33144509 DOI: 10.1073/pnas.2016067117 |
0.361 |
|
| 2020 |
Kong YW, Dreaden EC, Morandell S, Zhou W, Dhara SS, Sriram G, Lam FC, Patterson JC, Quadir M, Dinh A, Shopsowitz KE, Varmeh S, Yilmaz ÖH, Lippard SJ, Reinhardt HC, ... Hemann MT, et al. Enhancing chemotherapy response through augmented synthetic lethality by co-targeting nucleotide excision repair and cell-cycle checkpoints. Nature Communications. 11: 4124. PMID 32807787 DOI: 10.1038/S41467-020-17958-Z |
0.413 |
|
| 2020 |
Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, Elledge SJ, Hemann MT, Pritchard JR. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proceedings of the National Academy of Sciences of the United States of America. PMID 32041867 DOI: 10.1073/Pnas.1921649117 |
0.428 |
|
| 2019 |
Dalin S, Sullivan MR, Lau AN, Grauman-Boss B, Mueller HS, Kreidl E, Fenoglio S, Luengo A, Lees JA, Vander Heiden MG, Lauffenburger DA, Hemann MT. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance. Cancer Research. PMID 31484670 DOI: 10.1158/0008-5472.Can-19-0960 |
0.805 |
|
| 2019 |
Liu Y, Hemann MT. A dynamic view of chemotherapy effectiveness. Nature. 572: 321-322. PMID 31406309 DOI: 10.1038/D41586-019-02336-7 |
0.371 |
|
| 2019 |
Wojtaszek JL, Chatterjee N, Najeeb J, Ramos A, Lee M, Bian K, Xue JY, Fenton BA, Park H, Li D, Hemann MT, Hong J, Walker GC, Zhou P. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. PMID 31178121 DOI: 10.1016/J.Cell.2019.05.028 |
0.777 |
|
| 2019 |
Braun CJ, Hemann MT. Functional screens identify coordinators of RNA molecule birth, life, and death as targetable cancer vulnerabilities. Current Opinion in Genetics & Development. 54: 105-109. PMID 31121413 DOI: 10.1016/J.Gde.2019.04.003 |
0.331 |
|
| 2019 |
Dowling C, Dillion E, Hemann M, Cagney G, Letai A, Chonghaile TN. Abstract 5186: Discovery of a novel histone deacetylase 6 inhibitor that kills drug-resistant breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-5186 |
0.337 |
|
| 2019 |
Fiedler EC, Hemann MT. Aiding and Abetting: How the Tumor Microenvironment Protects Cancer from Chemotherapy Annual Review of Cancer Biology. 3: 409-428. DOI: 10.1146/ANNUREV-CANCERBIO-030518-055524 |
0.358 |
|
| 2018 |
Rizzo AA, Vassel FM, Chatterjee N, D'Souza S, Li Y, Hao B, Hemann MT, Walker GC, Korzhnev DM. Rev7 dimerization is important for assembly and function of the Rev1/Polζ translesion synthesis complex. Proceedings of the National Academy of Sciences of the United States of America. PMID 30111544 DOI: 10.1073/Pnas.1801149115 |
0.303 |
|
| 2018 |
Fiedler ERC, Bhutkar A, Lawler E, Besada R, Hemann MT. In vivo RNAi screening identifies as a target for combination therapy with TKIs in BCP-ALL. Blood Advances. 2: 1229-1242. PMID 29853524 DOI: 10.1182/Bloodadvances.2017015610 |
0.44 |
|
| 2018 |
Kauke MJ, Tisdale AW, Kelly RL, Braun CJ, Hemann MT, Wittrup KD. A Raf-competitive K-Ras binder can fail to functionally antagonize signaling. Molecular Cancer Therapeutics. PMID 29720559 DOI: 10.1158/1535-7163.Mct-17-0645 |
0.312 |
|
| 2018 |
Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, Ross L, Puissant A, Alexe G, Conway A, Back M, Pikman Y, Galinsky I, DeAngelo DJ, Stone RM, ... ... Hemann MT, et al. Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Science Translational Medicine. 10. PMID 29515000 DOI: 10.1126/Scitranslmed.Aam8460 |
0.349 |
|
| 2018 |
Ramos A, Barea LRM, Puissant A, Fenouille N, Alexe G, Stegmaier K, Hemann MT. Abstract 2358: Uncovering novel mechanisms of resistance in AML using integrative functional genomics Cancer Research. 78: 2358-2358. DOI: 10.1158/1538-7445.Am2018-2358 |
0.789 |
|
| 2017 |
Qi R, Wang Y, Bruno PM, Xiao H, Yingjie Y, Li T, Lauffer S, Wei W, Chen Q, Kang X, Song H, Yang X, Huang X, Detappe A, Matulonis U, ... ... Hemann MT, et al. Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nature Communications. 8: 2166. PMID 29255160 DOI: 10.1038/S41467-017-02390-7 |
0.407 |
|
| 2017 |
Braun CJ, Stanciu M, Boutz PL, Patterson JC, Calligaris D, Higuchi F, Neupane R, Fenoglio S, Cahill DP, Wakimoto H, Agar NYR, Yaffe MB, Sharp PA, Hemann MT, Lees JA. Coordinated Splicing of Regulatory Detained Introns within Oncogenic Transcripts Creates an Exploitable Vulnerability in Malignant Glioma. Cancer Cell. PMID 28966034 DOI: 10.1016/J.Ccell.2017.08.018 |
0.423 |
|
| 2017 |
Yamanaka K, Chatterjee N, Hemann MT, Walker GC. Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy? Plos Genetics. 13: e1006842. PMID 28817566 DOI: 10.1371/Journal.Pgen.1006842 |
0.476 |
|
| 2017 |
Tang YC, Yuwen H, Wang K, Bruno PM, Bullock K, Deik AA, Santaguida S, Trakala M, Pfau SJ, Zhong N, Huang T, Wang L, Clish CB, Hemann MT, Amon A. Aneuploid cell survival relies upon sphingolipid homeostasis. Cancer Research. PMID 28775166 DOI: 10.1158/0008-5472.Can-17-0049 |
0.446 |
|
| 2017 |
Ramos A, Hemann MT. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Cell. 170: 411-413. PMID 28753421 DOI: 10.1016/J.Cell.2017.07.018 |
0.772 |
|
| 2017 |
Miller TE, Liau BB, Wallace LC, Morton AR, Xie Q, Dixit D, Factor DC, Kim LJY, Morrow JJ, Wu Q, Mack SC, Hubert CG, Gillespie SM, Flavahan WA, Hoffmann T, ... ... Hemann MT, et al. Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature. PMID 28678782 DOI: 10.1038/Nature23000 |
0.415 |
|
| 2017 |
Soto-Feliciano YM, Bartlebaugh JME, Liu Y, Sánchez-Rivera FJ, Bhutkar A, Weintraub AS, Buenrostro JD, Cheng CS, Regev A, Jacks TE, Young RA, Hemann MT. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Genes & Development. PMID 28607179 DOI: 10.1101/Gad.295857.117 |
0.772 |
|
| 2017 |
Flamme M, Cressey P, Lu C, Bruno P, Eskandari A, Hemann M, Hogarth G, Suntharalingam K. Induction of necroptosis in cancer stem cells by a nickel(II)-dithiocarbamate phenanthroline complex. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28556445 DOI: 10.1002/Chem.201701837 |
0.367 |
|
| 2017 |
Bruno PM, Liu Y, Park GY, Murai J, Koch CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ, Hemann MT. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Nature Medicine. PMID 28263311 DOI: 10.1038/Nm.4291 |
0.435 |
|
| 2017 |
Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, ... ... Hemann MT, et al. The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nature Medicine. PMID 28191887 DOI: 10.1038/Nm.4283 |
0.787 |
|
| 2017 |
Dalin S, Zhao B, Hemann MT. Abstract PR07: Collateral sensitivity in chemotherapy resistance Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-Pr07 |
0.796 |
|
| 2016 |
Zhao B, Hemann MT, Lauffenburger DA. Modeling Tumor Clonal Evolution for Drug Combinations Design. Trends in Cancer. 2: 144-158. PMID 28435907 DOI: 10.1016/J.Trecan.2016.02.001 |
0.388 |
|
| 2016 |
Sun D, Dalin S, Hemann MT, Lauffenburger DA, Zhao B. Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations. Scientific Reports. 6: 36198. PMID 27819268 DOI: 10.1038/Srep36198 |
0.779 |
|
| 2016 |
Zheng YR, Suntharalingam K, Bruno PM, Lin W, Wang W, Hemann MT, Lippard SJ. Mechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage. Inorganica Chimica Acta. 452: 125-129. PMID 27818526 DOI: 10.1016/J.Ica.2016.03.021 |
0.345 |
|
| 2016 |
Eskandari A, Boodram JN, Cressey PB, Lu C, Bruno PM, Hemann MT, Suntharalingam K. The breast cancer stem cell potency of copper(ii) complexes bearing nonsteroidal anti-inflammatory drugs and their encapsulation using polymeric nanoparticles. Dalton Transactions (Cambridge, England : 2003). PMID 27774561 DOI: 10.1039/C6Dt03811E |
0.31 |
|
| 2016 |
Barnes JC, Bruno PM, Nguyen HV, Liao L, Liu J, Hemann MT, Johnson JA. Using an RNAi Signature Assay To Guide the Design of Three-Drug-Conjugated Nanoparticles with Validated Mechanisms, In Vivo Efficacy, and Low Toxicity. Journal of the American Chemical Society. PMID 27626288 DOI: 10.1021/Jacs.6B06321 |
0.314 |
|
| 2016 |
Bent EH, Gilbert LA, Hemann MT. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Genes & Development. PMID 27566778 DOI: 10.1101/Gad.284851.116 |
0.392 |
|
| 2016 |
Braun CJ, Hemann MT. Rewiring the solid tumor epigenome for cancer therapy. Expert Review of Anticancer Therapy. PMID 27410491 DOI: 10.1080/14737140.2016.1212663 |
0.373 |
|
| 2016 |
Cressey P, Eskandari A, Bruno P, Lu C, Hemann M, Suntharalingam K. The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells. Chembiochem : a European Journal of Chemical Biology. PMID 27377813 DOI: 10.1002/Cbic.201600368 |
0.391 |
|
| 2016 |
Pikman Y, Puissant A, Alexe G, Furman A, Chen LM, Frumm SM, Ross L, Fenouille N, Bassil CF, Lewis CA, Ramos A, Gould J, Stone RM, DeAngelo DJ, Galinsky I, ... ... Hemann MT, et al. Targeting MTHFD2 in acute myeloid leukemia. The Journal of Experimental Medicine. PMID 27325891 DOI: 10.1084/Jem.20151574 |
0.791 |
|
| 2016 |
Braun CJ, Bruno PM, Horlbeck MA, Gilbert LA, Weissman JS, Hemann MT. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Proceedings of the National Academy of Sciences of the United States of America. PMID 27325776 DOI: 10.1073/Pnas.1600582113 |
0.381 |
|
| 2016 |
Wilson JL, Dalin S, Gosline S, Hemann M, Fraenkel E, Lauffenburger DA. Pathway-based network modeling finds hidden genes in shRNA screen for regulators of acute lymphoblastic leukemia. Integrative Biology : Quantitative Biosciences From Nano to Macro. PMID 27315426 DOI: 10.1039/C6Ib00040A |
0.78 |
|
| 2016 |
Lindblad O, Cordero E, Puissant A, Macaulay L, Ramos A, Kabir NN, Sun J, Vallon-Christersson J, Haraldsson K, Hemann MT, Borg Å, Levander F, Stegmaier K, Pietras K, Rönnstrand L, et al. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML. Oncogene. PMID 26999641 DOI: 10.1038/Onc.2016.41 |
0.792 |
|
| 2016 |
Zhao B, Sedlak JC, Srinivas R, Creixell P, Pritchard JR, Tidor B, Lauffenburger DA, Hemann MT. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell. PMID 26924578 DOI: 10.1016/J.Cell.2016.01.045 |
0.574 |
|
| 2016 |
Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. Correction to "A Pt(IV) Pro-drug Preferentially Targets Indoleamine-2,3-dioxygenase, Providing Enhanced Ovarian Cancer Immuno-Chemotherapy". Journal of the American Chemical Society. PMID 26916820 DOI: 10.1021/Jacs.6B01316 |
0.347 |
|
| 2016 |
Boodram JN, Mcgregor IJ, Bruno PM, Cressey PB, Hemann MT, Suntharalingam K. Breast Cancer Stem Cell Potent Copper(II)-Non-Steroidal Anti-Inflammatory Drug Complexes. Angewandte Chemie (International Ed. in English). PMID 26806362 DOI: 10.1002/Anie.201510443 |
0.337 |
|
| 2016 |
Puissant A, Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, ... ... Hemann MT, et al. Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia Blood. 128: 523-523. DOI: 10.1182/Blood.V128.22.523.523 |
0.789 |
|
| 2016 |
Lossos C, Liu Y, Christie AL, Hemann MT, Weinstock DM. Harnessing the Tumor Microenvironment for the Treatment of Double Hit Lymphoma Blood. 128: 47-47. DOI: 10.1182/Blood.V128.22.47.47 |
0.366 |
|
| 2016 |
Dalin S, Zhao B, Hemann MT. Abstract 35: Evolution of resistance to glucocorticoid receptor agonists Clinical Cancer Research. 22: 35-35. DOI: 10.1158/1557-3265.Pmsclingen15-35 |
0.794 |
|
| 2016 |
Soto-Feliciano YM, Bartlebaugh JM, Liu Y, Sánchez-Rivera FJ, Weintraub AS, Bhutkar A, Jacks TE, Young RA, Hemann MT. Abstract A44: The role of PHF6 in maintaining pre-B cell commitment in B-cell acute lymphoblastic leukemia Cancer Research. 76. DOI: 10.1158/1538-7445.Chromepi15-A44 |
0.757 |
|
| 2016 |
Zhao B, Hemann MT, Lauffenburger DA. Modeling tumor clonal evolution for drug combinations design Trends in Cancer. 2: 144-158. DOI: 10.1016/j.trecan.2016.02.001 |
0.428 |
|
| 2016 |
Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K. Inside Back Cover: The Potent Inhibitory Effect of a Naproxen-Appended Cobalt(III)-Cyclam Complex on Cancer Stem Cells (ChemBioChem 18/2016) Chembiochem. 17: 1784-1784. DOI: 10.1002/Cbic.201600459 |
0.321 |
|
| 2015 |
Cannell IG, Merrick KA, Morandell S, Zhu CQ, Braun CJ, Grant RA, Cameron ER, Tsao MS, Hemann MT, Yaffe MB. A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy. Cancer Cell. 28: 831. PMID 28843280 DOI: 10.1016/J.Ccell.2015.11.003 |
0.395 |
|
| 2015 |
Shingleton JR, Hemann MT. The Chromatin Regulator CHD8 Is a Context-Dependent Mediator of Cell Survival in Murine Hematopoietic Malignancies. Plos One. 10: e0143275. PMID 26588464 DOI: 10.1371/Journal.Pone.0143275 |
0.459 |
|
| 2015 |
Awuah SG, Zheng YR, Bruno PM, Hemann MT, Lippard SJ. A Platinum(IV) Pro-drug Preferentially Targets IDO Providing Enhanced Ovarian Cancer Immuno-Chemotherapy. Journal of the American Chemical Society. PMID 26561720 DOI: 10.1021/Jacs.5B10182 |
0.455 |
|
| 2015 |
Zender L, Hemann M. Reconstitution of Mice with Modified Liver Stem Cells. Cold Spring Harbor Protocols. 2015: 685-8. PMID 26134904 DOI: 10.1101/Pdb.Prot078006 |
0.349 |
|
| 2015 |
Hemann M. Reconstitution of Mice with Modified Hematopoietic Stem Cells. Cold Spring Harbor Protocols. 2015: 679-84. PMID 26134903 DOI: 10.1101/Pdb.Prot077990 |
0.345 |
|
| 2015 |
McFaline-Figueroa JL, Braun CJ, Stanciu M, Nagel ZD, Mazzucato P, Sangaraju D, Cerniauskas E, Barford K, Vargas A, Chen Y, Tretyakova N, Lees JA, Hemann MT, White FM, Samson LD. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. Cancer Research. PMID 26025730 DOI: 10.1158/0008-5472.Can-14-3616 |
0.446 |
|
| 2015 |
Liu C, Ding H, Li X, Pallasch CP, Hong L, Guo D, Chen Y, Wang D, Wang W, Wang Y, Hemann MT, Jiang H. A DNA/HDAC dual-targeting drug CY190602 with significantly enhanced anticancer potency. Embo Molecular Medicine. 7: 438-49. PMID 25759362 DOI: 10.15252/Emmm.201404580 |
0.374 |
|
| 2015 |
Meacham CE, Lawton LN, Soto-Feliciano YM, Pritchard JR, Joughin BA, Ehrenberger T, Fenouille N, Zuber J, Williams RT, Young RA, Hemann MT. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Genes & Development. 29: 483-8. PMID 25737277 DOI: 10.1101/Gad.254151.114 |
0.778 |
|
| 2015 |
Suntharalingam K, Awuah SG, Bruno PM, Johnstone TC, Wang F, Lin W, Zheng YR, Page JE, Hemann MT, Lippard SJ. Necroptosis-inducing rhenium(V) oxo complexes. Journal of the American Chemical Society. 137: 2967-74. PMID 25698398 DOI: 10.1021/Ja511978Y |
0.314 |
|
| 2015 |
Puissant A, Fenouille N, Bassil CF, Ben-Sahra I, Alexe G, Benajiba L, Ramos A, Pikman Y, Burgess MR, Galinsky I, DeAngelo DJ, Stone RM, Shannon K, Hemann MT, Stegmaier K. Identification of CKMT1B As a New Target in EVI1-Positive AML Blood. 126: 3674-3674. DOI: 10.1182/Blood.V126.23.3674.3674 |
0.787 |
|
| 2015 |
Zhao B, Hemann MT, Lauffenburger DA. Abstract A31: Combination therapies guided by evolution of tumor heterogeneity. Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Hemmal14-A31 |
0.591 |
|
| 2015 |
Bruno PM, Park GY, Murai J, Liu Y, Pritchard J, Pommier Y, Lippard SJ, Hemann MT. Abstract C56: Platinum containing anti-cancer agents as targeted therapeutics Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-C56 |
0.44 |
|
| 2015 |
Hemann M. Chimeric tumor and organ transplantation models Cold Spring Harbor Protocols. 2015: 725-730. DOI: 10.1101/Pdb.Top069872 |
0.37 |
|
| 2015 |
Hemann M. Loss-of-function screening in hematopoietic malignancies Cold Spring Harbor Protocols. 2015: 740-742. DOI: 10.1101/Pdb.Prot078022 |
0.39 |
|
| 2015 |
Hemann M. Syngeneic transplants with modified chimeric hematopoietic tumors Cold Spring Harbor Protocols. 2015: 735-739. DOI: 10.1101/Pdb.Prot078014 |
0.342 |
|
| 2014 |
Zhao B, Hemann MT, Lauffenburger DA. Reply to Azuaje: Predicting effective combined therapies for heterogeneous tumors. Proceedings of the National Academy of Sciences of the United States of America. 111: E4288. PMID 25253893 DOI: 10.1073/Pnas.1415737111 |
0.518 |
|
| 2014 |
Suntharalingam K, Lin W, Johnstone TC, Bruno PM, Zheng YR, Hemann MT, Lippard SJ. A breast cancer stem cell-selective, mammospheres-potent osmium(VI) nitrido complex. Journal of the American Chemical Society. 136: 14413-6. PMID 25247635 DOI: 10.1021/Ja508808V |
0.383 |
|
| 2014 |
Zhao B, Hemann MT, Lauffenburger DA. Intratumor heterogeneity alters most effective drugs in designed combinations. Proceedings of the National Academy of Sciences of the United States of America. 111: 10773-8. PMID 25002493 DOI: 10.1073/Pnas.1323934111 |
0.508 |
|
| 2014 |
Hemann MT. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discovery. 4: 516-8. PMID 24795010 DOI: 10.1158/2159-8290.Cd-14-0316 |
0.354 |
|
| 2014 |
Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, Rönnstrand L, Kung AL, Aster JC, Galinsky I, Stone RM, DeAngelo DJ, ... Hemann MT, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 25: 226-42. PMID 24525236 DOI: 10.1016/J.Ccr.2014.01.022 |
0.379 |
|
| 2014 |
Pallasch CP, Leskov I, Braun CJ, Vorholt D, Drake A, Soto-Feliciano YM, Bent EH, Schwamb J, Iliopoulou B, Kutsch N, van Rooijen N, Frenzel LP, Wendtner CM, Heukamp L, Kreuzer KA, ... ... Hemann MT, et al. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Cell. 156: 590-602. PMID 24485462 DOI: 10.1016/J.Cell.2013.12.041 |
0.774 |
|
| 2014 |
Zhao B, Pritchard JR, Lauffenburger DA, Hemann MT. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discovery. 4: 166-74. PMID 24318931 DOI: 10.1158/2159-8290.Cd-13-0465 |
0.542 |
|
| 2014 |
Schwamb J, Reinart N, Vorholt D, Ulas T, Ristovska V, Braun CJ, Hemann MT, Schultze J, Hallek M, Pallasch CP. Phagocytic Function of Macrophages Is Impaired By Chronic Lymphocytic Leukemia and high–grade Lymphoma Progression and Can be Highly Effectively Restored for Chemo-Immunotherapy Blood. 124: 2727-2727. DOI: 10.1182/Blood.V124.21.2727.2727 |
0.392 |
|
| 2014 |
Pallasch C, Gilbert L, Hemann M. Abstract IA10: Improving existing cancer therapy by targeting the tumor microenvironment Molecular Cancer Research. 12. DOI: 10.1158/1557-3125.Modorg-Ia10 |
0.467 |
|
| 2014 |
Sánchez-Rivera FJ, Ryan J, Soto-Feliciano YM, Feldser DM, Hemann MT, Letai A, Jacks T. Abstract 2961: The level of mitochondrial apoptotic priming determines cell fate upon p53 restoration Cancer Research. 74: 2961-2961. DOI: 10.1158/1538-7445.Am2014-2961 |
0.801 |
|
| 2013 |
Suntharalingam K, Johnstone TC, Bruno PM, Lin W, Hemann MT, Lippard SJ. Bidentate ligands on osmium(VI) nitrido complexes control intracellular targeting and cell death pathways. Journal of the American Chemical Society. 135: 14060-3. PMID 24041161 DOI: 10.1021/Ja4075375 |
0.345 |
|
| 2013 |
Wilson JL, Hemann MT, Fraenkel E, Lauffenburger DA. Integrated network analyses for functional genomic studies in cancer. Seminars in Cancer Biology. 23: 213-8. PMID 23811269 DOI: 10.1016/J.Semcancer.2013.06.004 |
0.515 |
|
| 2013 |
Braun CJ, Hemann MT. Unraveling tumor suppressor networks with in vivo RNAi. Cell Stem Cell. 12: 639-41. PMID 23746971 DOI: 10.1016/J.Stem.2013.05.020 |
0.4 |
|
| 2013 |
Pavlova NN, Pallasch C, Elia AE, Braun CJ, Westbrook TF, Hemann M, Elledge SJ. A role for PVRL4-driven cell-cell interactions in tumorigenesis. Elife. 2: e00358. PMID 23682311 DOI: 10.7554/Elife.00358 |
0.428 |
|
| 2013 |
Pritchard JR, Bruno PM, Hemann MT, Lauffenburger DA. Predicting cancer drug mechanisms of action using molecular network signatures. Molecular Biosystems. 9: 1604-19. PMID 23287973 DOI: 10.1039/C2Mb25459J |
0.512 |
|
| 2013 |
Pritchard JR, Bruno PM, Gilbert LA, Capron KL, Lauffenburger DA, Hemann MT. Defining principles of combination drug mechanisms of action. Proceedings of the National Academy of Sciences of the United States of America. 110: E170-9. PMID 23251029 DOI: 10.1073/Pnas.1210419110 |
0.52 |
|
| 2013 |
Leskov I, Pallasch CP, Drake A, Iliopoulou BP, Souza A, Shen CH, Schweighofer CD, Abruzzo L, Frenzel LP, Wendtner CM, Hemann MT, Chen J. Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 32: 1066-72. PMID 22484426 DOI: 10.1038/Onc.2012.117 |
0.372 |
|
| 2013 |
Pikman Y, Puissant A, Alexe G, Frumm SM, Ross L, Chen L, Fenouille N, Bassil CF, Clish CB, Kung AL, Hemann MT, Banerji V, Stegmaier K. Targeting Folate Metabolism In Acute Myelogenous Leukemia Blood. 122: 3798-3798. DOI: 10.1182/Blood.V122.21.3798.3798 |
0.43 |
|
| 2013 |
Fenoglio S, Soto-Feliciano Y, Hannon G, Hemann M. Abstract A234: In vivo RNAi screening to identify major players in pancreatic tumor maintenance and growth. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A234 |
0.772 |
|
| 2013 |
Lauffenburger DA, Zhao B, Pritchard JR, Hemann MT. Abstract IA10: Targeting intratumoral genetic heterogeneity through rationally designed combination therapy Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Ia10 |
0.543 |
|
| 2012 |
Pritchard JR, Lauffenburger DA, Hemann MT. Understanding resistance to combination chemotherapy. Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy. 15: 249-57. PMID 23164555 DOI: 10.1016/J.Drup.2012.10.003 |
0.569 |
|
| 2012 |
Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes & Development. 26: 1758-68. PMID 22855834 DOI: 10.1101/Gad.197590.112 |
0.391 |
|
| 2012 |
Pallasch CP, Ilya L, Soto YM, Braun CJ, Kutsch N, Drake A, Frenzel LP, Iliopoulou B, van Rooijen N, Wendtner C, Hallek M, Chen J, Hemann MT. Drug-Induced Cytokine Release Sensitizes Protective Tumor Microenvironments to Antibody- Mediated Therapy Blood. 120: 1335-1335. DOI: 10.1182/Blood.V120.21.1335.1335 |
0.445 |
|
| 2012 |
Lauffenburger DA, Pritchard JR, Hemann MT. Abstract SY22-02: Mammalian functional genetic signatures identify efficacy landscapes of combination chemotherapy Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Sy22-02 |
0.544 |
|
| 2012 |
Sánchez-Rivera FJ, Feldser DM, Doench J, Bhutkar A, Meacham CE, Root DE, Hemann MT, Jacks T. Abstract 2957: Uncovering tumor-specific components of the p53 pathway using mouse models and RNAi Cancer Research. 72: 2957-2957. DOI: 10.1158/1538-7445.Am2012-2957 |
0.725 |
|
| 2011 |
Pritchard JR, Gilbert LA, Meacham CE, Ricks JL, Jiang H, Lauffenburger DA, Hemann MT. Bcl-2 family genetic profiling reveals microenvironment-specific determinants of chemotherapeutic response. Cancer Research. 71: 5850-8. PMID 21784872 DOI: 10.1158/0008-5472.Can-11-1014 |
0.557 |
|
| 2011 |
Gilbert LA, Hemann MT. Chemotherapeutic resistance: surviving stressful situations. Cancer Research. 71: 5062-6. PMID 21771909 DOI: 10.1158/0008-5472.Can-11-0277 |
0.439 |
|
| 2011 |
Stadanlick JE, Zhang Z, Lee SY, Hemann M, Biery M, Carleton MO, Zambetti GP, Anderson SJ, Oravecz T, Wiest DL. Developmental arrest of T cells in Rpl22-deficient mice is dependent upon multiple p53 effectors. Journal of Immunology (Baltimore, Md. : 1950). 187: 664-75. PMID 21690328 DOI: 10.4049/Jimmunol.1100029 |
0.371 |
|
| 2011 |
Jiang H, Pritchard JR, Williams RT, Lauffenburger DA, Hemann MT. A mammalian functional-genetic approach to characterizing cancer therapeutics. Nature Chemical Biology. 7: 92-100. PMID 21186347 DOI: 10.1038/Nchembio.503 |
0.538 |
|
| 2011 |
Hemann MT. Abstract IA25: Using old mouse models to identify new cancer drug targets Cancer Research. 71. DOI: 10.1158/1538-7445.Fbcr11-Ia25 |
0.507 |
|
| 2010 |
Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA, Sanchez-Rivera FJ, Resnick R, Bronson R, Hemann MT, Jacks T. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature. 468: 572-5. PMID 21107428 DOI: 10.1038/Nature09535 |
0.703 |
|
| 2010 |
Xie K, Doles J, Hemann MT, Walker GC. Error-prone translesion synthesis mediates acquired chemoresistance. Proceedings of the National Academy of Sciences of the United States of America. 107: 20792-7. PMID 21068378 DOI: 10.1073/Pnas.1011412107 |
0.449 |
|
| 2010 |
Doles J, Oliver TG, Cameron ER, Hsu G, Jacks T, Walker GC, Hemann MT. Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. Proceedings of the National Academy of Sciences of the United States of America. 107: 20786-91. PMID 21068376 DOI: 10.1073/Pnas.1011409107 |
0.458 |
|
| 2010 |
Gilbert LA, Hemann MT. DNA damage-mediated induction of a chemoresistant niche. Cell. 143: 355-66. PMID 21029859 DOI: 10.1016/J.Cell.2010.09.043 |
0.413 |
|
| 2010 |
Doles J, Hemann MT. Nek4 status differentially alters sensitivity to distinct microtubule poisons. Cancer Research. 70: 1033-41. PMID 20103636 DOI: 10.1158/0008-5472.Can-09-2113 |
0.376 |
|
| 2009 |
Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell. 16: 324-35. PMID 19800577 DOI: 10.1016/J.Ccr.2009.08.015 |
0.369 |
|
| 2009 |
Meacham CE, Ho EE, Dubrovsky E, Gertler FB, Hemann MT. In vivo RNAi screening identifies regulators of actin dynamics as key determinants of lymphoma progression. Nature Genetics. 41: 1133-7. PMID 19783987 DOI: 10.1038/Ng.451 |
0.462 |
|
| 2009 |
Christian Reinhardt H, Jiang H, Hemann MT, Yaffe MB. Exploiting synthetic lethal interactions for targeted cancer therapy Cell Cycle. 8: 3112-3119. PMID 19755856 DOI: 10.4161/Cc.8.19.9626 |
0.422 |
|
| 2009 |
Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Molecular Cancer Therapeutics. 8: 2183-92. PMID 19671754 DOI: 10.1158/1535-7163.Mct-08-1203 |
0.565 |
|
| 2009 |
Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response Genes and Development. 23: 1895-1909. PMID 19608766 DOI: 10.1101/Gad.1815309 |
0.406 |
|
| 2008 |
Burgess DJ, Doles J, Zender L, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. Proceedings of the National Academy of Sciences of the United States of America. 105: 9053-8. PMID 18574145 DOI: 10.1073/Pnas.0803513105 |
0.464 |
|
| 2008 |
Hemann M. Abstract ED05-03: The development of tractable mouse models to study therapeutic response Cancer Prevention Research. 1. DOI: 10.1158/1940-6207.Prev-08-Ed05-03 |
0.447 |
|
| 2007 |
Hemann MT, Narita M. Oncogenes and senescence: breaking down in the fast lane. Genes & Development. 21: 1-5. PMID 17210783 DOI: 10.1101/Gad.1514207 |
0.407 |
|
| 2006 |
Hemann MT, Lowe SW. The p53-Bcl-2 connection. Cell Death and Differentiation. 13: 1256-9. PMID 16710363 DOI: 10.1038/Sj.Cdd.4401962 |
0.414 |
|
| 2005 |
Dickins RA, Hemann MT, Zilfou JT, Simpson DR, Ibarra I, Hannon GJ, Lowe SW. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nature Genetics. 37: 1289-95. PMID 16200064 DOI: 10.1038/Ng1651 |
0.303 |
|
| 2005 |
Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, Cleveland JL, Tansey WP, Lowe SW. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 436: 807-11. PMID 16094360 DOI: 10.1038/Nature03845 |
0.367 |
|
| 2005 |
Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. Embo Reports. 6: 177-83. PMID 15678160 DOI: 10.1038/Sj.Embor.7400333 |
0.338 |
|
| 2004 |
Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature. 430: 797-802. PMID 15306814 DOI: 10.1038/Nature02820 |
0.41 |
|
| 2004 |
Hemann MT, Zilfou JT, Zhao Z, Burgess DJ, Hannon GJ, Lowe SW. Suppression of tumorigenesis by the p53 target PUMA. Proceedings of the National Academy of Sciences of the United States of America. 101: 9333-8. PMID 15192153 DOI: 10.1073/Pnas.0403286101 |
0.365 |
|
| 2003 |
Hemann MT, Fridman JS, Zilfou JT, Hernando E, Paddison PJ, Cordon-Cardo C, Hannon GJ, Lowe SW. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nature Genetics. 33: 396-400. PMID 12567186 DOI: 10.1038/Ng1091 |
0.398 |
|
| 2002 |
Hathcock KS, Hemann MT, Opperman KK, Strong MA, Greider CW, Hodes RJ. Haploinsufficiency of mTR results in defects in telomere elongation. Proceedings of the National Academy of Sciences of the United States of America. 99: 3591-6. PMID 11904421 DOI: 10.1073/Pnas.012549799 |
0.566 |
|
| 2001 |
Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107: 67-77. PMID 11595186 DOI: 10.1016/S0092-8674(01)00504-9 |
0.671 |
|
| 2001 |
Hemann MT, Rudolph KL, Strong MA, DePinho RA, Chin L, Greider CW. Telomere dysfunction triggers developmentally regulated germ cell apoptosis. Molecular Biology of the Cell. 12: 2023-30. PMID 11452000 DOI: 10.1091/Mbc.12.7.2023 |
0.615 |
|
| 2000 |
Hemann MT, Hackett J, IJpma A, Greider CW. Telomere length, telomere-binding proteins, and DNA damage signaling. Cold Spring Harbor Symposia On Quantitative Biology. 65: 275-9. PMID 12760041 DOI: 10.1101/Sqb.2000.65.275 |
0.735 |
|
| 2000 |
Hemann MT, Greider CW. Wild-derived inbred mouse strains have short telomeres. Nucleic Acids Research. 28: 4474-8. PMID 11071935 DOI: 10.1093/Nar/28.22.4474 |
0.564 |
|
| 1999 |
Hemann MT, Greider CW. G-strand overhangs on telomeres in telomerase-deficient mouse cells. Nucleic Acids Research. 27: 3964-9. PMID 10497259 DOI: 10.1093/Nar/27.20.3964 |
0.603 |
|
| Show low-probability matches. |